Gilead said its twice-yearly HIV PrEP injection Yeztugo topped Wall Street expectations as sales exceeded $1 billion for the franchise. In Q2, Yeztugo generated $232 million versus estimates of $221 million, bolstered by continued adoption of the injectable prevention option in appropriate patient populations.